Primary rhabdomyosarcomas (RMS) of the nose and paranasal sinuses is very rare in adults, and this treatment is usually conducted based on standardized therapy protocols such as the German Cooperative Soft Tissue Sarcoma Study (CWS) and the Intergroup Rhabdomyosarcoma Study (IRS).
We report a case of paranasal sinus RMS.
A 57-year old man seen for epistaxis, underwent multimodality treatment surgery, chemotherapy (VAC: vincristine, actinomycin D and cyclophosphamide), and radiation. When RMS remained, we switched from VAC to cyclophosphamide and topotecan (CT) reported in a pediatric oncology group Phase II study. The man survived 6 years and 2 monhts.
